Skip to main content

Table 2 Predictors of intact fibroblast growth factor 23 (iFGF23): linear regression analysis

From: Intact fibroblast growth factor 23 in heart failure with reduced and mildly reduced ejection fraction

 

Univariate analysis

Multivariate analysis

p

Beta

p

Beta

Age

0.126

-0.180

  

Gender (male)

0.652

0.053

  

BMI

0.472

0.076

  

NYHA class

0.786

0.036

  

Atrial fibrillation

0.374

-0.089

  

Peak VO2/kg

0.008

-0.362

0.075

-0.115

LVEF

0.722

-0.044

  

LVMI

0.009

0.320

0.001

0.297

PAPs

0.115

0.189

  

E/e’

0.471

-0.085

  

Haemoglobin

0.756

-0.062

  

eGFR

< 0.001

-0.423

< 0.001

-0.323

PTH

0.424

0.223

  

Phosphate

0.054

0.156

0.105

0.126

Calcium

0.406

0.163

  

25-hydroxyvitamin D3

0.528

0.113

  

NT-proBNP

0.480

-0.195

  

PRA

0.934

-0.016

  

Aldosterone

0.319

0.205

  

Epinephrine

0.814

-0.019

  

Norepinephrine

0.369

0.073

  

ACEi

0.502

0.079

  

ARBs

0.781

-0.032

  

Beta blockers

0.601

-0.043

  

MRAs

0.810

0.019

  

Diuretics

0.763

0.025

  
  1. Continuous variables were ln-transformed for analysis. The multivariable model included univariate predictors with p < 0.10 (highlighted in bold). ACEi, angiotensin-converting-enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; eGFR, estimated glomerular filtration rate; LVEF, left ventricular ejection fraction; LVMI, left ventricular mass index; MRA, mineralocorticoid receptor antagonist; NT-proBNP, N-terminal pro B-type natriuretic peptide; PAPs, pulmonary artery systolic pressure; PRA, plasma renin activity; PTH, parathormone
Back to article page

BMC Cardiovascular Disorders

ISSN: 1471-2261

Contact us